Synendos Therapeutics expands Series A round

Synendos Therapeutics, a biopharmaceutical company focused on treating central nervous system disorders, has expanded its Series A round to CHF 24 million.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this